Reference priceBRL R$3,412.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Metopiron Kapseln |
|---|---|
| Manufacturer | HRA-Pharma Switzerland Sàrl |
| Prescription required | Yes |
Metopiron Kapseln 250mg(Metyrapone)
Metyrapone
Description
Metopiron Kapseln 250mg(Metyrapone) is a medicine catalog record in the MediPriceHub database. Active ingredient: Metyrapone. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: HRA-Pharma Switzerland Sàrl. Therapeutic category: Medicine Library > Oncology Medicines > Adrenocortical Carcinoma. Pack information: 250 / 50. Origin country or market: Switzerland. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients.How to Use
Was sollte dazu beachtet werden? Wie verwenden Sie Metopiron? Diagnostische Anwendung Therapeutische AnwendungSpecification
Active ingredient: Metyrapone. Pack size: 250 / 50. Pack unit: bottle. Manufacturer: HRA-Pharma Switzerland Sàrl. Origin country: Switzerland. Source category: Medicine Library > Oncology Medicines > Adrenocortical Carcinoma. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Esta informação é apenas para referência. Consulte um profissional de saúde antes de usar qualquer medicamento.